US0463531089 - ADR
NASDAQ:AZN (9/27/2022, 2:42:04 PM)+0.17 (+0.32%)
|GICS Sector||Health Care|
|Earnings (Last)||07-29 2022-07-29/bmo||Earnings (Next)||N/A N/A|
|Ins Owners||N/A||Inst Owners||17.28%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. The company is headquartered in Cambridge, Cambridgeshire and currently employs 83,100 full-time employees. The company went IPO on 2007-09-21. The firm focuses on discovery and development, manufacturing and commercialization of prescription medicines. The firm is focused on various therapy areas, such as Oncology; BioPharmaceuticals (comprising Cardiovascular, Renal & Metabolism (CVRM) and Respiratory & Immunology (R&I)), and Rare Disease. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 177 projects, of which 161 are in the clinical phase of development. Its key marketed oncology products include Tagrisso (osimertinib), Lynparza (olaparib), Imfinzi (durvalumab), Koselugo (selumetinib), Farxiga/ Forxiga (dapagliflozin), Roxadustat, Onglyza (saxagliptin) and others. The Company’s geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia.
ASTRAZENECA PLC-SPONS ADR
1 Francis Crick Avenue
Cambridge CAMBRIDGESHIRE CB2 0AA
CEO: Pascal Soriot
Investors have seven widely-followed vaccine stocks to sell now, after the world decided the pandemic is over.
Though successful in early testing, it wasn't enough to win a Phase 3 study.
Here you can normally see the latest stock twits on AZN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.